Thanks, very interesting. My guess is the antibodi

Thanks, very interesting. My guess is the antibodies they're developing are against the CD4 binding arm on the HIV virus itself. The antibodies alone might not be 100% effective on their own but a powerful CCR5 blocker like leronlimab could boost effectiveness. Of course where CCR5 occupancy is 100% another antibody would be superfluous. They may also be developing antibodies against dual CXCR4/CCR5 dual strains where their antibody blocks CXCR4 binding and leronlimab could block CCR5.